How GlaxoSmithKline plc Gave Away $2bn!

A newly floated US biotech company has achieved a valuation of $2.2bn. Good for them, you say? You might not think that if you’re a GlaxoSmithKline (LSE: GSK) shareholder and you learn who Axovant got its sole product from — and what it paid!

Elsewhere in the market, the Fool's experts believe sales could treble in just five years at this e-commerce stealth attack whose maverick CEO may have been underestimated by the City. For more free information on this daring buy, click here now.

Owain Bennallack owns shares in GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.